SOPHiA GENETICS (SOPH) to Release Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) will be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.12). The firm had revenue of $17.05 million for the quarter, compared to analysts’ expectations of $16.78 million. SOPHiA GENETICS had a negative return on equity of 47.40% and a negative net margin of 126.63%. During the same quarter in the previous year, the company posted ($0.22) EPS. On average, analysts expect SOPHiA GENETICS to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SOPHiA GENETICS Stock Down 1.6 %

NASDAQ SOPH opened at $5.00 on Friday. SOPHiA GENETICS has a 52-week low of $2.13 and a 52-week high of $7.37. The firm has a 50-day moving average price of $4.93 and a 200 day moving average price of $4.53. The stock has a market capitalization of $326.15 million, a P/E ratio of -4.10 and a beta of 1.12.

Analysts Set New Price Targets

Several analysts have recently commented on the company. BTIG Research raised their price target on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a report on Wednesday, March 6th.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.